Skip to main content
main-content

Tip

Swipe om te navigeren naar een ander artikel

02-05-2018 | Original Article - E‑Learning | Uitgave 6/2018 Open Access

Netherlands Heart Journal 6/2018

Optimal long-term antithrombotic management of atrial fibrillation: life cycle management

Tijdschrift:
Netherlands Heart Journal > Uitgave 6/2018
Auteurs:
R. Pisters, A. Elvan, H. J. G. M. Crijns, M. E. W. Hemels

Abstract

Optimal antithrombotic management of atrial fibrillation equals balancing between prevention of arterial thromboembolism, predominantly ischaemic stroke, and haemorrhagic complications. Over time different antithrombotic agents and strategies have been developed. At present, non-vitamin K antagonist oral anticoagulants (NOACs) are the first-line therapy for stroke prevention in patients with non-valvular atrial fibrillation (i.e. without a mechanical valve prosthesis or rheumatic heart disease). Considering the impact of the suboptimal adoption of recommended oral anticoagulant therapy, as experienced with the previous first-line vitamin K antagonists, this review focuses on adequate use of NOACs. As such, we address the most important and clinically challenging issues in the antithrombotic life cycle management for long-term stroke prevention in atrial fibrillation.

Onze productaanbevelingen

Netherlands Heart Journal

Het Netherlands Heart Journal wordt uitgegeven in samenwerking met de Nederlandse Vereniging voor Cardiologie en de Nederlandse Hartstichting. Het tijdschrift is Engelstalig en wordt gratis beschikbaa ...

Literatuur
Over dit artikel

Andere artikelen Uitgave 6/2018

Netherlands Heart Journal 6/2018Naar de uitgave

Image Puzzle – Answer

Cough up your lungs